Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04604522 · ClinicalTrials.gov registry record
Evaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans Syndrome
A clinical trial of Bronchiolitis Obliterans, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 15
- Enrollment target
- 1
- Study location
NCT04604522 is a study of Bronchiolitis Obliterans that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants, below the 407-participant average among 9 other Bronchiolitis Obliterans trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04604522, a study of Bronchiolitis Obliterans, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study investigates a type of cell, called abnormal clonogenic epithelial cells, in patients with bronchiolitis obliterans syndrome who have had an donor stem cell transplant or a lung transplant. Learning more about clonogenic cells in these patients may help doctors to detect signs of bronchiolitis obliterans syndrome earlier in future patients.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Medical Chart Review
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-08-27 |
| Est. Completion | 2026-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04604522
The ClinicalTrials.gov registry entry for NCT04604522 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 407-participant average among 9 other Bronchiolitis Obliterans trials with a reported enrollment target (96% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bronchiolitis Obliterans appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT04604522 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04604522 about?
NCT04604522 is a clinical study titled "Evaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans Syndrome". This study investigates a type of cell, called abnormal clonogenic epithelial cells, in patients with bronchiolitis obliterans syndrome who have had an donor stem cell transplant or a lung transplant. Learning more about clonogenic cells in these patients may help doctors to detect signs of bronchio...
What is the current status of trial NCT04604522?
This trial is currently recruiting. The enrollment target is 15 participants. The study started on 2020-08-27. Estimated completion is 2026-03-31.
What conditions does trial NCT04604522 study?
This clinical trial studies the following conditions: Bronchiolitis Obliterans.
What interventions are being tested in trial NCT04604522?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Medical Chart Review (OTHER).
Who is sponsoring clinical trial NCT04604522?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04604522 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bronchiolitis Obliterans
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
RECRUITING
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
-
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
COMPLETED · Phase 3
-
Hp129 Xenon Imaging and BOS in Lung Transplantation
COMPLETED · Phase 1
-
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.